Atrix Laboratories Inc has received approval from the US FDA to market fluticasone propionate cream, 0.05 per cent. A first generic fluticasone cream to be approved by the FDA, Sandoz Inc., a Novartis company, is marketing this new generic product.

On April 27, 2004, the company announced the tentative approval of the Abbreviated New Drug Application (ANDA). Atrix's product is the AB-rated generic to topical Cutivate (fluticasone propionate cream) cream 0.05 per cent, which is marketed by GlaxoSmithKline PLC. Cutivate cream's patent expired on May 14, 2004.

This product is typically used as a topical anti-inflammatory, anti-pruritic agent.